; (iv) whether use of kratom or kratom-derived products is directly linked to the use of more dangerous scheduled substances; (v) any adverse health impacts that could be expected if kratom or kratom-derived were no longer available; and (vi) the potential health and wellness benefits of kratom and kratom-derived products. (3) Public docket Not later than 30 days after the date of enactment of this Act, the Secretary shall open a public docket for submission of public comments for consideration at the hearing under paragraph (1). The Secretary shall leave such public docket open for comments for not fewer than 30 days before the hearing takes place. (4) Publication of information The Secretary shall publish on the website of the Food and Drug Administration the transcripts of all hearings conducted pursuant to paragraph (1), subject to section 552(b) of title 5, United States Code. (b) Task force (1) Establishment Not later than 30 days after the date of enactment of this Act, the Secretary shall convene a task force, to be known as the Kratom Research Task Force , to coordinate kratom-related research conducted or supported by the Federal Government. (2) Reports on kratom research (A) Initial report Not later than 90 days after the date of enactment of this Act, the Kratom Research Task Force shall submit to Congress, the Secretary, and the Commissioner a report that details all federally funded kratom-related research that has begun or been completed prior to such date of enactment. (B) Subsequent quarterly reports Not later than 90 days after submission of the report under subparagraph (A), and quarterly thereafter, the Kratom Research Task Force shall submit to Congress, the Secretary, and the Commissioner a report that includes— (i) a progress report on all federally funded kratom-related research and findings made during the applicable quarter